Clinical trial
ATEMPT 2.0: Adjuvant T-DM1 vs TH
NCT04893109
Study timeline
Study start (actual)2021-06-16Date precision: day
Registry last updated2026-08-19
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Interventions
Sponsors & collaborators
Dana-Farber Cancer Institutelead sponsor
Genentech, Inc.collaborator
Mapped research locations
BostonMassachusetts, United States3New YorkNew York, United States2NashvilleTennessee, United States2IndianapolisIndiana, United States2HoustonTexas, United States1ChicagoIllinois, United States1PhiladelphiaPennsylvania, United States1MiamiFlorida, United States1San FranciscoCalifornia, United States1PittsburghPennsylvania, United States1ColumbusOhio, United States1DurhamNorth Carolina, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04893109 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.